Global Cardiology IT Workflow Solutions Market Report 2023-2030 - Rise of IT in Healthcare Provides the Foundation for Adoption
30 nov. 2023 03h08 HE
|
Research and Markets
Dublin, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The "Cardiology IT Workflow Solutions - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Cardiology IT...
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
21 nov. 2023 16h30 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
26 oct. 2023 08h30 HE
|
Tenaya Therapeutics, Inc.
PKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated to Affect 70,000 People in the US TN-401 Preclinical Studies Demonstrated...
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
25 oct. 2023 06h50 HE
|
ZyVersa Therapeutics
Obesity exacerbates scarring of the heart through ASC-driven inflammasome activation in the heart leading to damaging inflammation.
Cardiovascular Disease Prevalence Sparks Demand in Global Perfusion Disposables Market - Report Analyzes Market Insights Across 39 Countries with Focus on Valvular Health
17 oct. 2023 06h53 HE
|
Research and Markets
Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "Perfusion Disposables Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures...
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
09 oct. 2023 08h30 HE
|
Tenaya Therapeutics, Inc.
TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants Combination of Tenaya’s HDAC6...
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
05 oct. 2023 08h30 HE
|
Tenaya Therapeutics, Inc.
Tenaya Therapeutics announced that the first patient has been dosed with TN-201 gene therapy.
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration
02 oct. 2023 17h30 HE
|
Tenaya Therapeutics, Inc.
Tenaya announced the publication of preclinical research in the October 3, 2023, issue of the American Heart Association’s journal, Circulation.
Global Cardiac Arrest Treatment Market: Forecasted Growth to Reach USD 8.3 Billion by 2030, At a CAGR of 4.5%
02 oct. 2023 17h29 HE
|
Zion Market Research
NEW YORK, United States, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Cardiac Arrest Treatment Market By Treatment (Drugs [Vasopressors,...
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
21 sept. 2023 16h05 HE
|
Tenaya Therapeutics, Inc.
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study...